BioCentury
ARTICLE | Clinical News

Maxim completes Phase III enrollment

October 9, 2000 7:00 AM UTC

Maxim (MAXM; SSE:MAXM) completed enrollment of 300 patients in its Phase III trial of Maxamine to treat acute myelogenous leukemia (AML). The international trial combines Maxamine with IL-2, and will ...